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ABSTRACT
Objective To determine the incidence of cervical cancer
after several negative cervical smear tests at different
ages.
Design Prospective observational study of incidence of
cervical cancer after the third consecutive negative result
based on individual level data in a national registry of
histopathology and cytopathology (PALGA).
Setting Netherlands, national data.
Population 218847 women aged 45-54 and 445382
aged 30-44 at the time of the third negative smear test.
Main outcome measures 10 year cumulative incidence of
interval cervical cancer.
Results 105 women developed cervical cancer within
2595964 woman years at risk after the third negative
result at age 30-44 and 42 within 1278532 woman years
at risk after age 45-54. During follow-up, both age groups
had similar levels of screening. After 10 years of follow-
up, the cumulative incidence rate of cervical cancer was
similar: 41/100000 (95% confidence interval 33 to 51) in
the younger group and 36/100000 (24 to 52) in the older
group (P=0.48). The cumulative incidence rate of cervical
intraepithelial neoplasia grade I+ was twice as high in the
younger than in the older group (P<0.001).
Conclusions The risk for cervical cancer after several
negative smear results by age 50 is similar to the risk at
younger ages. Even after several negative smear results,
age is not a good discriminative factor for early cessation
of cervical cancer screening.
INTRODUCTION
The debate on early cessation of cervical cancer
screening forwomenwith several consecutive negative
smear results and no abnormalities by age 50 has been
ongoing for about 15 years, with no clear conclusions
in terms of a change to guideline for these women. Sev-
eral authors have studied this issue by analysing the
detection rates of preinvasive cervical lesions in these
women.1-9 In general, they observed considerably
lower detection rates than in similarly screened
younger women. On the basis of this finding they
argued that continued screening in this particular
group of women is not as efficient as screening
among younger women and could be stopped at the
expense of only a limited increase in the incidence of
cervical cancer among these older women.2 4 6 9 This
could result in considerable savings for the screening
programmes. In the Netherlands, for example, it
would apply to about half of the women attending
screening around age 50.10
Because there is strong evidence that cervical intra-
epithelial neoplasia lesions have a higher probability to
progress to invasive cancer at older ages,11 12 a lower
detection rate after age 50 alone does not represent
conclusive evidence for lower screening efficiency.
Data on invasive cancer have since become available
in a Dutch nationwide pathology registry with screen-
ing histories linked to diagnostic histological outcomes
(including cancer) at the individual level. We mea-
sured the incidence of invasive cancer after several
consecutive negative smear results in women around
age 50 and in younger women. This bypasses the pro-
blems associated with using cervical intraepithelial
neoplasia lesions and enables a more conclusive eva-
luation of whether there ismore reason to relax screen-
ing in older than in younger women with similar
negative screening histories.
METHODS
Data
From the Dutch nationwide network and registry of
histopathology and cytopathology (PALGA), we
retrieved information on all cervix uteri cytological
and histological tests until 31March 2004. In principle,
all pathology laboratories in the Netherlands partici-
pate in this computerised system. The registration
began in the late 1970s and achieved practically com-
plete coverage of pathology laboratories in 1990.13 The
network registers smears and biopsies taken in all set-
tings: primary smears within the screening pro-
gramme, opportunistic screening, or because of
medical complaints, and secondary (diagnostic and fol-
low-up) tests, regardless of whether they are taken or
read by public or private healthcare providers and
laboratories. The retrieved file contained data for all
but one pathology laboratory, accounting for less
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than 1% of smears taken yearly. In the Netherlands,
cervical cancer screening became widespread after an
extensive pilot project that started in 1976. Around
1980, the programme inviting women aged 35-53
with a three year interval reached almost national cov-
erage. A considerable amount of opportunistic screen-
ing in young women coexisted next to the organised
programme,14 and the programme was reorganised in
1996. Women are now invited once every five years
between ages 30 and 60.15 In 2003, 77% of women at
risk (that is, those with a cervix) in this age group had
had at least one smear in the preceding five years.16 The
most commonly used screening tool is a conventional
Pap smear, although the share of liquid based cytology
smears is increasing.
In the network, women are identified through their
birth date and the first four letters of their (maiden)
family name. This identification code enabled linkage
of the tests belonging to the same woman, allowing us
to follow the individual screening anddisease histories.
Because this code is not always unique, it introduces an
upwardbias in the incidence after a negative screen.To
avoid this bias, we excluded women with 0.5% of the
most common first four letters of the family name—
that is, about 30% of women. The cut-off point of
0.5% was chosen because we observed that the inci-
dence of cervical cancer after a negative result stabi-
lised around this point.17 An independent analysis
comparing the network data with a regional dataset
with virtually no incorrectmatches of the identification
code showed that this was an adequate method of
avoiding the problem of incorrect identification
matches.18
Final diagnoses for all non-cancer excerpts (that is,
all cytology and all non-cancer biopsies) in the
retrieved network file were based on the network’s
SNOMED (systemised nomenclature of medicine)
oriented codes. In contrast, we identified cases of cer-
vical cancer by (manually) checking the free text of the
pathology reports for all excerpts that included
SNOMED-oriented codes for cervical cancer for the
period 1994-2002. The follow-up (person years at risk
and cases) in the present analysis was therefore left cen-
sored at the beginning of 1994 and right censored at the
end of 2002. Figure 1 shows a schematic presentation
of the study.
Statistical analysis
We selected women in two age groups, 45-54 (“the
older group”) and 30-44 (“the younger group”) and
included them if they had a third consecutive negative
primary smear result in this age interval at any time
since the beginning of the registration. Women with
previous histological (cervical intraepithelial neoplasia
grade I+) or cytological (borderline dyskaryosis or
worse) abnormalitieswere excluded.Womenwere fol-
lowedup from thedate of the thirdnegative smear until
the date of the first diagnosis of cervical cancer or until
the end of 2002. We could not censor the follow-up in
case of death from other causes because we had no
information on the time of death. However, we
estimate that the potential impact on our results was
small because themortality rate in women in theNeth-
erlands below age 65 is low (below 1% per year since
the 1980s).19
For both age groups, we first calculated the cumula-
tive incidence rate of cervical cancer in the period
1994-2002 by time since the third negative result.
Because for most women (about 85% in the older
group and 80% in the younger group) a maximum of
10 years of follow-up was available, we focused on the
cumulative incidence rate during these first 10 years.
We tested the difference in the cumulative incidence
rate between the age groups for significance assuming
a Poisson distribution for the number of women with
cancer—that is, cases (null hypothesis: no difference in
the cumulative incidence rate between the age groups).
We estimated the 95% confidence intervals using the
non-parametric Kaplan-Meier product limit estimator
for log(hazard).20 We tested the difference in the inci-
dence rates between the two age groups during the
whole follow-up period (the hazard rate) by Cox
regression with left and right censoring. Time depen-
dency of relative hazards was tested by splitting the
total follow-up time in two periods with a roughly
equal number of cases.
RESULTS
We identified 218 847 women in the older group and
445 382 in the younger group who met our inclusion
criteria (table 1). The average interval between the
three consecutive negative results (that is, between
the first and the second, and the second and the third
smear) was 40 months in the older group and
39 months in the younger group, reflecting the fact
that women could accumulate the three registered
negative smears either in about the 20 years before
1996, when recommendations tried to limit screening
to once in three years, or in the seven years since 1996
to 2002, with the recommendation of one smear per
five years. In the period between 1 January 1994 and
31December 2002, 1.3 and 2.6million person years in
follow-up accrued in these groups, respectively, an
average of 5.84 and 5.83 years per woman (table 2).
The two groups had a similar rate of screening after the
third negative smear (table 3): about a third had none,
Counted consecutive smears
Counted consecutive smears, person years at risk, and cases
31 Dec
2002
Time
1 Jan
1994
Late
1970s
Fig 1 |Schematic presentation of study. Consecutive primary
smears counted throughout entire period covered by PALGA
system (from late 1970s onwards), whereas person years at
risk and cases counted from 1 January 1994 to 31 December
2002. Person years and cases accrued before 1 January 1994
excluded from analysis (left censoring)
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about a third had one, and the remaining third had
more than one further primary test registered. Forty
two women in the older group and 105 women in the
younger group developed cervical cancer (table 2).
During follow-up, the difference in the cumulative
incidence rate between the age groups was never sig-
nificant (fig 2 and table 2). Table 4 shows the average
absolute yearly incidence rates.
The average age of women was 37.3 years in the
younger group and 48.7 years in the older group. Pool-
ing women into two large age groups does not seem to
have affected this result, as the cumulative incidence
rate for cervical cancer at 10 years in smaller five year
age groups also did not differ significantly (table 1,
P=0.24).
The overall hazard ratio was 0.84 (95% confidence
interval 0.59 to 1.21) for the older compared with the
younger group. The test for time dependency of the
relative hazards was non-significant (P=0.86).
We also varied the criterion for study eligibility from
requiring three to requiring either two or four consecu-
tive negative results. This changed the absolute level of
risk but not the relation between the two age groups.
Table 1 | Description of study population by five year age groups
Age 30-44 at entry Age 45-54 at entry
30-34 35-39 40-44 45-49 50-54
No of women 126 748 156 435 162 199 124 254 94 593
CIR† 36 (23 to 58) 39 (26 to 59) 45 (32 to 61) 38 (22 to 66) 33 (21 to 53)
†Cumulative incidence rate (95% CI) per 100 000 women at 10 years after third consecutive negative smear result.
Table 2 | Incidence of invasive cervical cancer after third consecutive negative smear result for two age groups
Time (years) since
third negative smear
Age (years) at entry
P value‡
30-44 45-54
Woman
years*
Women with
invasive cancer
Cumulative
incidence rate†
(95% CI)
Woman
years*
Women with
invasive cancer
Cumulative
incidence rate†
(95% CI)
≤1 324 512 4 1 (0 to 3) 172 920 3 2 (1 to 5) 0.66
>1-≤3 628 471 16 6 (4 to 10) 344 825 16 11 (7 to 17) 0.09
>3-≤5 563 725 27 16 (12 to 21) 304 194 5 14 (10 to 21) 0.65
>5-≤10 837 359 43 41 (33 to 51) 378 075 13 36 (24 to 52) 0.48
>10-≤15 200 225 11 70 (51 to 95) 65 373 4 73 (39 to 135) 0.85
>15−≤20 41 672 4 128 (79 to 207) 13 145 1 105 (50 to 219) 0.27
Total 2 595 964 105 — 1 278 532 42 — —
*Accrued between 1 January 1994 and 31 December 2002.
†At end point of interval, per 100 000 women.
‡Two sided, for difference in rate between two age groups at specific time points.
Table 3 | Percentage of primary screening tests after third
consecutive negative smear result*
No of tests
Age (years) at entry
30-44 45-54
0 35 35
1 27 33
2 18 18
3 10 8
≥4 10 7
Total 100 100
*Average number of years at risk for further smears after third negative
smear was 6.7 and 6.4 among women aged 30-44 and 45-45,
respectively.
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Fig 2 | Cumulative incidence rate for invasive cancer by age
group and time since third consecutive negative smear result
Table 4 | Incidence rates per 100 000 woman years at risk
(95% CI) by age group and year in follow-up
Time (years) since
third negative smear
Age (years) at entry
30-44 45-54
1 0.10 (0.04 to 0.27) 0.14 (0.05 to 0.45)
2 0.08 (0.03 to 0.24) 0.10 (0.02 to 0.38)
3 0.32 (0.18 to 0.57) 0.68 (0.40 to 1.15)
5 0.40 (0.27 to 0.58) 0.14 (0.06 to 0.33)
7 0.46 (0.31 to 0.69) 0.15 (0.06 to 0.41)
9 0.33 (0.19 to 0.58) 0.38 (0.17 to 0.85)
11 0.52 (0.29 to 0.94) 0.52 (0.19 to 1.38)
13 0.28 (0.09 to 0.88) 0.58 (0.15 to 2.32)
15 0.77 (0.29 to 2.04) 0.64 (0.09 to 4.46)
20 0.78 (0.29 to 2.07) 0.62 (0.09 to 4.37)
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After two consecutive negative results, the 10 year
cumulative incidence rate for cancer was 45/100 000
(39 to 52) in the younger group and 48/100 000 (38 to
61) in the older group. Within 10 years after four con-
secutive negative smears, the cumulative incidence
rate in the younger group was 47/100 000 (34 to 65),
whereas in the older group it was 26/100 000 (14 to 47).
By 15 years, however, the cumulative incidence rate
after four consecutive negative smears in the older
group caught up with that in the younger group
(74/100 000 (45 to 121) in the younger group and
82/100 000 (26 to 257) in the older group).
We also calculated the cumulative incidence rate
with cervical intraepithelial neoplasia grade I+ as the
end point (table 5, fig 3). By 10 years, the cumulative
incidence rate was 1258/100 000 (1209 to 1308) in the
younger group and 594/100 000 (547 to 645) in the
older group. The difference between both groups was
significant throughout the entire follow-up. Use of cer-
vical intraepithelial neoplasia grade II+ or grade III+
as the end point instead of grade I+ also showed that
preinvasive lesions are more commonly detected in
the younger groups. The cumulative incidence rate of
cervical intraepithelial neoplasia grade II+ was
721/100 000 (684 to 759) among younger and
258/100 000 (227 to 293) among older women. The
cumulative incidence rate of cervical intraepithelial
neoplasia grade III+ was 445/100 000 (417 to 476)
among younger and 165/100,000 (140 to 194) among
older women.
DISCUSSION
The relative risk of developing cervical cancer after a
third consecutive negative smear result amongwomen
around age 50 did not differ significantly from the risk
in younger women. This outcome was not biased by
differential screening during follow-up because there
was no difference between the age groups in this
respect. Evidence available in the literature does not
show that either the differential screening sensitivity
for high grade cervical intraepithelial neoplasia or the
differential effectiveness of treatment of screen
detected cervical intraepithelial neoplasia, in the con-
text of the overall highly successful treatment and a
decreasing detection of cervical intraepithelial neopla-
sia with increasing age, differ between these two age
groups to such a degree that they would bias our
conclusions.21-26 Therefore it is reasonable to assume
that after several consecutive negative results the
screening efficiency in terms of detection and preven-
tion of cervical cancer is at the same level around age
50 as it is at younger ages.
In the analysed age groups (30-54 years), the inci-
dence rate of cervical cancer in the general population
was between10 and14 per 100 000womanyears in the
period 2001-5.27 These rates are a reflection of different
screening histories including those of well screened
women included in our analysis, where the latter tend
to decrease the general population incidence rates.
Whether the relatively low incidence rates observed
in both our study groups warrant continued screening
should thus be determined by subsequent analyses.
We observed a lower risk for cervical intraepithelial
neoplasia grades I+, II+, and III+ in the older group.
In this respect, our results are consistent with those of
others,2 4 6 and confirm that cervical intraepithelial neo-
plasia is not an accurate intermediate end point for the
question addressed.
Because we included women as soon as they had the
third consecutive negative result, younger women will
on average have been screened more intensely at a
younger age than women included in the older
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Fig 3 | Cumulative incidence rate for cervical intraepithelial
neoplasia grade I+ (CIN I+) by age group and time since third
consecutive negative smear result
Table 5 | Incidence of cervical intraepithelial neoplasia I+ (CIN I+) after third consecutive negative smear result for two age groups
Time (years) since third
negative smear
Age (years) at entry
P value‡
30-44 45-54
Woman years* Women with CIN I+
Cumulative incidence
rate† (95% CI) Woman years* Women with CIN I+
Cumulative incidence
rate† (95% CI)
≤1 324 381 233 72 (63 to 82) 172 850 90 52 (42 to 64) 0.008
>1-≤3 627 524 584 258 (241 to 277) 344 441 172 152 (135 to 172) <0.001
>3-≤5 561 412 834 555 (529 to 583) 303 363 240 310 (284 to 339) <0.001
>5-≤10 829 336 1192 1258 (1209 to 1308) 375 786 224 594 (547 to 645) <0.001
>10-≤15 196 753 197 1707 (1622 to 1796) 64 635 30 769 (686 to 862) <0.001
>15−≤20 40 898 24 1986 (1841 to 2143) 12 995 5 920 (772 to 1096) <0.001
Total 2 580 304 3064 — 1 274 070 761 — —
*Accrued between 1 January 1994 and 31 December 2002.
†At end point of interval, per 100 000 women.
‡Two sided for difference in rate between two age groups at specific time points.
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group; the older women might therefore be at higher
risk. The selection criterion of being disease free on
three consecutive screenings, however, and the finding
that the screening attendance after the third negative
result was similar in both groupsmake such a bias unli-
kely. We tested this in an additional analysis in which
we included women from the younger group in the
older group if they continued to have negative smears
after age 44. The resultwas the same: in the older group
the 10 year cumulative incidence rate slightly
decreased from 36 (24 to 52) to 34 (25 to 48) per
100 000.
We selected women with negative screening his-
tories—that is, women who had never had cytological
or histological evidence of neoplasia. In everyday
practice, complete screening histories might not
always be known and might contain abnormalities.
Women with previous abnormalities—that is, at least
abnormal cytology—remain at higher risk for invasive
cancer, despite later consecutive negative smear
results.28 In our data, inclusion of women with screen
detected abnormalities followed by three consecutive
primary negative results did not affect the two age
groups differently: the cumulative incidence rate at
10 years was 42 (30 to 57)/100 000 in the older group
and 42 (34 to 51)/100 000 in the younger group.
Implications of the study
The similarity in the cumulative incidence rate
between the two age groups is not unexpected given
the observed age specific incidence before screening
became widespread29 (that is, before about 1970 in
most developed countries). In the Netherlands, as
well as in several western European countries, the inci-
dence before screening rose rapidly to a peak around
ages 44-49 anddeclined thereafter.Thus,whenwomen
in the 30-44 year group (average age about 37) are age-
ing, they proceed froma lower to a higher risk age. The
opposite is true for women in the 45-54 year group
(average age about 50). This translates into roughly
equal levels of cumulative incidence rate for cancer
during the first 10 years for the two age groups (that
is, from age 37 to 47, and from 50 to 60 years,
respectively).29 In some other countries, like the Uni-
ted Kingdom and the United States, the decline in the
incidence before screening at older ages is slower. If
this pattern is because of a real different age effect and
not a cohort effect, the relative reduction in incidence
of cancer gained through continued screening in the
older group would be even higher than in the Nether-
lands.
The question of age specific screening efficiency can
be further explored by comparing the average number
of life years lost per extra incident case if screening had
been discontinued after three negative smear results.
Younger women have a longer remaining life expec-
tancy than older women, but they also have lower
death rates from cervical cancer. The life expectancy
of women in the Netherlands is 42, 33, and 24 years at
ages 40, 50, and 60, respectively,30 while the five year
mortality rate from clinical cervical cancer
(approximated by stage IIB+) increases from about
45% to 70% and 70-75%, respectively, at the same
ages.31 Assuming that the five year mortality rates
approximate the total death, around 20 years are lost
per incident case in the absence of screening for all
three ages, which means that decreasing life expec-
tancy and the increasing cancer death compensate
each other. At even older ages, however, the number
of life years lost per incident case starts to decrease.
Our data do not permit a simple extension of our
study to older ages. For example, in 79 586 women
satisfying the criteria at ages 55-64, the 10 year cumu-
lative incidence rate was 47/100 000 (23 to 99) andwas
statistically comparable with that in women below age
55. Women aged 55-64 years, however, had a consid-
erably lower screening intensity after the thirdnegative
result: 60% had no further smear compared with 35%
inwomenbelowage55. Inwomenabove 64, screening
intensity decreases even further. This diminishes the
actual comparability of women aged 55 or older with
women below that age, and, as a consequence, we can-
not draw clear conclusions on the relative screening
efficiency for this age group.
The continued risk for cervical cancer is consistent
with the considerable rate of (apparently) incident
human papillomavirus (HPV) infections throughout
the age span we focused on.32 33 As it is the screen
detected cervical intraepithelial neoplasia rather than
an HPV infection that can be treated, HPV screening
instead of cytological screening could eliminate rela-
tively few extra HPV infections before the age of 50.
In case of HPV screening, our conclusions would
therefore remain the same. This would also mean that
the HPV vaccine might succeed in attaining its full
potential of eradicating up to 70% of cervical cancer
only if it offers protection from a persistent HPV infec-
tion for many decades—that is, also after age 50. This
again will depend strongly on the (unknown) propor-
tion of infections at age 50 and over that are caused by
reactivated latent infections acquired earlier in life.34 35
From the UK data on the timing of screening smears
before the (pseudo-) diagnosis of cervical cancer in
cases and controls, Sasieni et al showed that the protec-
tion a negative smear offers to youngerwomen (age 20-
39) is lower than among women aged 40 or older.36 As
a consequence, they advocated shorter screening inter-
vals for younger than for olderwomen.Thedifferences
in our results are consistent with two important differ-
ences between studies. Firstly, in the UK data older
women had probably accumulated more screening
tests before the analysed negative smear than younger
women. A lower number of earlier smears tends to
increase the subsequent incidence of cervical cancer.
In our analysis, women had similar screening histories
(three consecutive negative results before the begin-
ning of follow-up). Secondly, the increase in the risk
for cervical cancer among younger British cohorts
might have played a role.37 No such increase has
been observed in the Netherlands.38
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Conclusions
Bybeing able to use invasive cancer as the relevant end
point, our analysis gives amore evidence based answer
to the ongoing discussion on continued screening in
women with several negative smear results by age 50.
It showed that it would not be consistent to stop screen-
ing these women while not also relaxing the screening
policy for younger women with similar screening his-
tories. In this respect, our conclusion lends support to
the current cervical cancer screening guidelines in
England and other developed countries,36 39-42 which
do not discriminate women by age up to 60-65.
Whether individual tailoring of recommendations
for further screening by using the information on indi-
vidual screening histories would be an efficient and
feasible alternative to the current fixed schedule in
any age group remains to be explored.
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